Zealand Pharma presents positive clinical and health economic outcome data with use of regular human insulin delivered by the V-Go in adults with type 2 diabetes Results of this 14-week randomized ...
MannKind Corporation reported positive results from its Phase 3 trial of Afresa (insulin human [rDNA origin]) inhalation powder evaluating its effects on glycemic control and pulmonary function over a ...
Phase 3 pulmonary function safety data for Afresa (insulin human [rDNA origin] inhalation powder, from MannKind Corp.) was presented at the American Diabetes Association’s (ADA) 69th Scientific ...
Nastech Announces Positive Phase 1 Clinical Results of Insulin Nasal Spray Compared to Exubera(R) Inhalation Powder and NovoLog(C) Insulin Aspart Injection Study shows Insulin Nasal Spray provides the ...
BRIDGEWATER, N.J., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, ...
The FDA told MannKind Corp. in a complete response letter that before the agency could approve the firm's inhaled diabetes drug Afrezza (insulin human rDNA origin), regulators needed more information ...
SAN FRANCISCO, March 23, 2010 — Scientists today described a new ultra-rapid acting mealtime insulin (AFREZZA™) that is orally inhaled for absorption via the lung. Because the insulin is absorbed so ...
VALENCIA, Calif. & NEW YORK--(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) and Pfizer Inc (NYSE: PFE) announced today that MannKind will transition certain Exubera patients with a continuing ...
On its third try before the FDA, Mannkind Corp.'s inhaled insulin Afrezza (insulin human [rDNA origin]) finally won approval Friday, capping nearly eight years of dogged pursuit in the wake of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback